ADC Therapeutics SA current report, Q2 FY2021

ADC Therapeutics SA Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by ADC Therapeutics SA, a Swiss foreign private issuer, on April 6, 2021, for the month of April 2021. The filing identifies the company’s principal executive office in Epalinges, Switzerland and indicates that it files annual reports on Form 20-F.

Financial Metrics

The filing cover page does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.

Material Changes Versus Prior Period

The filing text does not provide financial or operational comparisons with a prior comparable period.

Guidance, Outlook, Risks, and Unusual Items

The filing identifies Exhibit 99.1 as a press release dated April 6, 2021, but the press release content is not included in the provided filing text. Accordingly, guidance, management commentary, risks, contingencies, and unusual items cannot be assessed.

Investor Verification Items

  • Obtain and review Exhibit 99.1, the April 6, 2021 press release.
  • Verify whether the press release contains material clinical, regulatory, financing, corporate, or commercial updates.
  • Review the company’s applicable Form 20-F and subsequent filings for financial metrics and developments.